Molecular heterogeneity of triple-negative breast cancer

被引：58
作者：
Abramson V.G. [1 ]
Mayer I.A. [1 ]
机构：
[1] Division of Hematology/Oncology/Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-6307, 2220 Pierce Avenue
来源：
Current Breast Cancer Reports | 2014年 / 6卷 / 3期
关键词：
Gene expression profiles; Targeted therapy; TNBC; Triple-negative breast cancer;
D O I：
10.1007/s12609-014-0152-1
中图分类号：
学科分类号：
摘要：
Triple-negative breast cancers (TNBCs) are a group of aggressive breast cancers with a greater incidence of relapse, stage-for-stage, than ER/PR-positive and HER2-positive breast cancers, despite optimum loco-regional and systemic therapy. To date, no single targeted therapy has been approved for treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analysis identified six distinct TNBC subtypes, each with unique biology. In this review we discuss current and forthcoming therapeutic strategies and novel approaches to targeted treatment of these TNBC subtypes. © 2014 Springer Science+Business Media.
引用
收藏
页码：154 / 158
页数：4
相关论文
共 36 条
  • [1] Perou C.M., Sorlie T., Eisen M.B., Van De Rijn M., Jeffrey S.S., Rees C.A., Et al., Molecular portraits of human breast tumours, Nature, 406, 6797, pp. 747-752, (2000)
  • [2] Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., Et al., Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin Cancer Res, 10, 16, pp. 5367-5374, (2004)
  • [3] Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., Et al., Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype, Clin Cancer Res off J Am Assoc Cancer Res, 14, 5, pp. 1368-1376, (2008)
  • [4] Fulford L.G., Easton D.F., Reis-Filho J.S., Sofronis A., Gillett C.E., Lakhani S.R., Et al., Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast, Histopathology, 49, 1, pp. 22-34, (2006)
  • [5] Fulford L.G., Reis-Filho J.S., Ryder K., Jones C., Gillett C.E., Hanby A., Et al., Basal-like grade III invasive ductal carcinoma of the breast: Patterns of metastasis and long-term survival, Breast Cancer Res BCR, 9, 1, (2007)
  • [6] Arnes J.B., Brunet J.S., Stefansson I., Begin L.R., Wong N., Chappuis P.O., Et al., Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer, Clin Cancer Res off J Am Assoc Cancer Res, 11, 11, pp. 4003-4011, (2005)
  • [7] Subhawong A.P., Subhawong T., Nassar H., Kouprina N., Begum S., Vang R., Et al., Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically, Am J Surg Pathol, 33, 2, pp. 163-175, (2009)
  • [8] Reis-Filho J.S., Savage K., Lambros M.B., James M., Steele D., Jones R.L., Et al., Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: An immunohistochemical and chromogenic in situ hybridisation analysis, Modern Pathol off J United States Can Acad Pathol Inc, 19, 7, pp. 999-1009, (2006)
  • [9] Rakha E.A., Ellis I.O., Reis-Filho J.S., Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas), Modern Pathol off J United States Can Academy Pathol Inc, 21, 8, pp. 1060-1061, (2008)
  • [10] Bertucci F., Finetti P., Cervera N., Esterni B., Hermitte F., Viens P., Et al., How basal are triple-negative breast cancers?, Int J Cancer, 123, 1, pp. 236-240, (2008)
1234